welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Welcome to your weekly digest of approaching regulatory and clinical readouts. Novavax is up 4% today thanks to topline results from a phase II trial showing that its Nanoflu influenza vaccine caused “vigorous immune responses” to four strains of flu, and that these responses were enhanced when the group’s Matrix-M adjuvant was added to the vaccine.
But an even more meaningful event is approaching. Novavax’s lead asset, a vaccine against respiratory syncytial virus, is in phase III, and after its disastrous failure two years ago in a study that was intended to be pivotal this is its last chance.
Resvax, also known as RSV F Vaccine since it targets the fusion protein of the virus, crashed out of the Resolve trial, testing it in prevention of moderate to severe RSV-associated lower respiratory tract disease, in mid-2016.
expertly curated content related to this topic
Extracolonic Manifestations of Hereditary Colorectal Cancer SyndromesFamilial colorectal adenocarcinoma (CRC)...
Prevalence and Risk Factors for Adenomas in the Ileal Pouch and the Afferent Loop After Restorative Proctocolectomy ...BACKGROUND : Restorative proctocolectomy...
Desmoid Tumors — Dangerous when not Treated as Cancerhttps://www.youtube.com/watch?v=gPcEJ8kA...
Colorectal Cancer: Are Genetic Tests Clinically Useful?More than 1.2 million new cases of color...
Health Promotion: Familial Adenomatous Polyposishttps://www.youtube.com/watch?v=H7STJHsN...
Evaluating Causes of Death in Familial Adenomatous PolyposisBACKGROUND : Familial adenomatous polypo...